Last reviewed · How we verify

NCT05804994

Evaluate the Efficacy and the Tolerance of the Medical Device V063B-DP3003 on Dentin Hypersensitivity During Teeth Whitening

Completed NA Last updated 18 June 2024
What this trial tests

NA trial testing Elgydium Clinic Sensileave Gel (V063B - DP3003) in Tooth Whitening in 88 participants. Completed in 13 December 2023.

Timeline
30 April 2023
Primary endpoint
13 December 2023
13 December 2023

Quick facts

Lead sponsorPierre Fabre Dermo Cosmetique
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingnone
Primary purposesupportive care
Enrollment88
Start date30 April 2023
Primary completion13 December 2023
Estimated completion13 December 2023
Sites1 location across Poland

Drugs / interventions tested

Conditions studied

Sponsor

Pierre Fabre Dermo Cosmetique — full company profile →

Who can join

Adults 18 to 65, any sex, with Tooth Whitening. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A dental gel intended to relieve pain related to dentin hyper sensitivity is commercialized in several countries worlwide since May 2017. Its efficacy and tolerance has already been proven in dentin hyper sensitivity. In this new study, we assess the efficacy and tolerance of this tested product in a specific external agression, the teeth whitening.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other Pierre Fabre Dermo Cosmetique trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05804994.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing